Skip to main content

LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Completed · Not applicable · NCT04790344

Conditions: Heart Failure

At a glance

Research payments reported, 2025
$624,430
U.S. investigators named
60
Sites paid
58
Planned or actual enrollment
557

About the trial

Sponsor
Boston Scientific Corporation
Tested
Investigational LUX-Dx ICM Implant (device)
Dates
Started 2021-03-20; completion 2026-07-27
Results posted
Not yet

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

From ClinicalTrials.gov, last updated 2026-10-05. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $624,430 in research payments for this study in 2025 (271 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.